Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT00392821 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT00392821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2006
Completion date
October 31, 2013
Enrollment
78 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer